Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-003050-96-IT
EUCTR2005-003050-96-IT
Active, not recruiting
Not Applicable

Multicentre, prospective, assessor-blind, in parallel groups randomised and vs reference marketed product controlled confirmatory trial of the efficacy and safety of IBSA BMV medicated plaster for the treatment of chronic plaque psoriasis

IBSA0 sites180 target enrollmentJanuary 19, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionschronic plaque psoriasisMedDRA version: 9.1Level: LLTClassification code 10033898Term: Parapsoriasis
DrugsBetneval 0.1% crema

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
chronic plaque psoriasis
Sponsor
IBSA
Enrollment
180
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 19, 2007
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
IBSA

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Comparison of efficacy and safety of Betesil® medicated plaster versus Daivobet®/Dovobet® ointment in the treatment of chronic plaque psoriasisChronic plaque psoriasisSkin and Connective Tissue DiseasesPsoriasis
ISRCTN34974208Institut Biochimique SA (IBSA) (Switzerland)300
Completed
Phase 3
Efficacy and safety of Institut Biochimique SA (IBSA) 0.1% betamethasone valerate (BMV) medicated plaster versus reference marketed product for the treatment of chronic plaque psoriasis
ISRCTN68864186Institut Biochimique SA (IBSA) (Switzerland)180
Active, not recruiting
Not Applicable
Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil, IBSA-Institut Biochimique S.A.) versus 50μg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet/Dovobet, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis. - ND
EUCTR2009-016969-28-ITIBSA INSTITUT BIOCHIMIQUE SA300
Active, not recruiting
Phase 1
Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil®, IBSA-Institut Biochimique S.A.) versus 50µg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet®/Dovobet®, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis.
EUCTR2009-016969-28-FRIBSA, Institut Biochimique SA
Completed
Phase 3
A Phase III clinical trial of Teriparatide in postmenopausal women with osteoporosis
CTRI/2021/04/032769Intas Pharmaceuticals Ltd